Objective: To compare infants" discomfort, nursing-time and caregiver preference, and assess the clinical efficiency (as a secondary outcome) of hood versus facemask nebulization in infants with evolving bronchopulmonary dysplasia (BPD) in the neonatal intensive care unit. Study Design: A prospective, open, randomized, controlled crossover clinical trial. In total, 10 infants with BPD who were on inhaled beta-agonist bronchodilators and corticosteroids were randomly assigned to receive their nebulized treatments either by a facemask, or by a hood for 2-3 days, and then crossover to receive the same treatments with the other technique for another 2-3 days. Infants' discomfort, nursing-time, caregiver preference and clinical efficiency were compared. Results: At baseline there was no significant clinical difference between the groups. Nurse-time required for administering the hood nebulization (mean±s.e.m.: 1.9±0.1 min) was significantly shorter than the time for mask nebulization (12.0plusmn;0.6min, P<0.0001). Infants discomfort score was significantly lower (0.1±0.04) for hood versus mask nebulization (2.5±0.2, P<0.0001). Nurses and parents unequivocally preferred the hood treatment. During both mask and hood nebulization therapies (2-3 days) clinical efficiency was comparable. While both methods caused an immediate (20min post) clinical improvement, the immediate respiratory assessment change score was significantly greater for the hood versus the mask nebulization (0.62±0.27 versus 0.13±0.14, P<0.05). Conclusions: Nebulization of aerosolized medications in infants with evolving BPD by hood was less time-consuming for caregivers and was much better tolerated by the infants while being at least as effective as the conventional facemask nebulization.
- Bronchopulmonary dysplasia
- Neonatal intensive care unit